Russian Journal of ImmunologyRussian Journal of Immunology1028-72212782-7291Russian Society of Immunology117710.46235/1028-7221-1177-COIResearch ArticleCooperation of idiotypic and anti-idiotypic antibodies at the steroid-depended chemical carcinogenesisPolenokElena G.<p>PhD (Pharmacy), Leading Research Associate, Laboratory of Immunochemistry, Institute of Human Ecology, Federal Research Center of Coal and Coal Chemistry</p>egpolenok@mail.ruhttps://orcid.org/0000-0002-9368-2340GordeevaLyudmila A.<p>PhD (Biology), Leading Research Associate, Laboratory of Immunogenetics, Institute of Human Ecology, Federal Research Center of Coal and Coal Chemistry</p>gorsib@rambler.ruhttps://orcid.org/0000-0001-5870-7584MunStella M.<p>PhD (Medicine), Senior Research Associate, Laboratory of Immunogenetics, Institute of Human Ecology, Federal Research Center of Coal and Coal Chemistry</p>stellamun@yandex.ruhttps://orcid.org/0000-0002-5530-3469KostyankoMikhail V.<p>Leading Engineer, Department of Organic Chemistry, Institute of Fundamental Sciences, Kemerovo State University</p>kmvksu@mail.ruhttps://orcid.org/0000-0003-0053-1752AntonovAlexander V.<p>Chief, Breast Cancer Department, Kuzbass M. Rappoport Clinical Oncology Dispensary</p>al0412@mail.ruhttps://orcid.org/0000-0003-0802-9759VerzhbitskajaNatalia E.<p>PhD (Medicine), Clinical Pathologist, Pathology Department, Kuzbass M. Rappoport Clinical Oncology Dispensary</p>verzhbitskaia@mail.ruhttps://orcid.org/0000-0003-3860-825XBairamovPavel V.<p>Head, Pathology Department, Kuzbass M. Rappoport Clinical Oncology Dispensary</p>bayramov_pavel82@mail.ruKolpinskiyGleb I.<p>PhD, MD (Medicine), Professor, Department of Radiology, Radiotherapy and Oncology, Kemerovo State Medical University; Main Physician, Kemerovo Clinical Diagnostic Сenter</p>Glebss@mail.ruhttps://orcid.org/0000-0002-5526-2687VafinIlgiz A.<p>Main Physician, Kuzbass Center of Blood</p>gkuz.kots@yandex.ruGlushkovAndrey N.<p>PhD, MD (Medicine), Professor, Chief Research Associate, Laboratory of Immunogenetics, Institute of Human Ecology, Federal Research Center of Coal and Coal Chemistry</p>glushkovan@ihe.sbras.ruhttps://orcid.org/0000-0002-8560-6719Institute of Human Ecology, Federal Research Center of Coal and Coal chemistryInstitute of Fundamental Sciences, Kemerovo State UniversityKuzbass M. Rappoport Clinical Oncology DispensaryKuzbass Clinical Oncology DispensaryKemerovo State Medical UniversityKemerovo Clinical Diagnostic СenterKuzbass Center of Blood2212202226127401507202208112022Copyright © 2022, Polenok E.G., Gordeeva L.A., Mun S.M., Kostyanko M.V., Antonov A.V., Verzhbitskaja N.E., Bairamov P.V., Kolpinskiy G.I., Vafin I.A., Glushkov A.N.2022<p>Immunological research of steroid-depended chemical carcinogenesis in humans is based on positive experience in the clinical usage of selective estrogen receptor modulators and experimental design of immunological methods for human protection from environmental carcinogens. Our study aimed for research of idiotypic antibodies against benzo[a]pyrene, estradiol and progesterone (IgA<sub>1</sub>-Bp, IgA<sub>1</sub>-E2 and IgA<sub>1</sub>-Pg), in connection with anti-idiotypic antibodies specific to estradiol and progesterone (IgG<sub>2</sub>-E2 and IgG<sub>2</sub>-Pg) in serum samples of postmenopausal healthy women (HW) and ER<sup>+</sup>/PR<sup>+</sup> stage I breast cancer patients (BCP). Idiotypic antibodies were studied in 402 HW and 475 BCP using ELISA technique, with BP, E2 and Pg conjugated with bovine serum albumin as adsorbed antigens. The anti-idiotypic antibodies were studied using ELISA method and monoclonal antibodies against E2 and Pg as adsorbed antigens. High individual ratios of IgA<sub>1</sub>-Bp/ IgA<sub>1</sub>-Pg 1 and IgA<sub>1</sub>-E2/IgA<sub>1</sub>-Pg 1 were revealed in 42.1% and 48.5% HW, and in 71.1% and 78.1% of BCP cases (p 0.0001, OR = 5.9 and OR = 3.8, respectively). High IgG<sub>2</sub>-E2 4 levels were found in 23.4% HW and in 41.2% of BCP group (p = 0.0001, OR = 2.3). Combination of IgA<sub>1</sub>-Bp/IgA<sub>1</sub>-Pg 1 with IgG<sub>2</sub>-E2 4 and IgG<sub>2</sub>-Pg 2 was more common in HW, than in BCP (29.3%<em> vs </em>5.8%, p 0.0001, OR = 0.1). Combinations of IgA<sub>1</sub>-Bp/IgA<sub>1</sub>-Pg 1with IgG<sub>2</sub>-E2 4 or with IgG<sub>2</sub>-Pg 2 were more frequent in BCP, than in HW (12.0% and 31.8%<em> vs </em>4.9% and 15.2%, accordingly, p = 0.01, OR = 2.7 and p = 0.001, OR = 2.6), as well as combination of IgA<sub>1</sub>-Bp/IgA<sub>1</sub>-Pg 1 with IgG<sub>2</sub>-E2 4 and IgG<sub>2</sub>-Pg 2 (23.4%<em> vs </em>9.8%, p = 0.0003, OR = 2.8). Similar specific features were found in HW and BCP when studying IgA<sub>1</sub>-E2/IgA<sub>1</sub>-Pg ratio with IgG<sub>2</sub>-E2 and IgG<sub>2</sub>-Pg. Nevertheless, high IgA<sub>1</sub>-Bp/IgA<sub>1</sub>-Pg 1 or IgA<sub>1</sub>-E2/IgA<sub>1</sub>-Pg 1 combined with low IgG<sub>2</sub>-E2 4 + IgG<sub>2</sub>-Pg 2 were revealed in HW (27.7% and 28.8%) more frequently, than in BCP (19.7%, p = 0.06 and 17.9%, p = 0.008). Excess of IgA<sub>1</sub>-Bp and IgA<sub>1</sub>-E2 levels over IgA<sub>1</sub>-Pg in combination with high IgG<sub>2</sub>-E2 and IgG<sub>2</sub>-Pg levels in HW is associated with ER<sup>+</sup>/PR<sup>+</sup> BC stage I condition and may serve as an marker for preventive BC therapy by the targeted ER modulators.</p>idiotypic antibodiesantiidiotypic antibodiesbenzo[a]pyreneestradiolprogesteronecancerидиотипические антителаантиидиотипические антителабензо[а]пиренэстрадиолпрогестеронрак[Глушков А.Н., Поленок Е.Г., Костянко М.В., Титов В.А., Вафин И.А., Рагожина С.Е. Взаимное влияние антител к бензо[a]пирену, эстрадиолу и прогестерону на риски возникновения рака легкого // Российский иммунологический журнал, 2015. Т. 9 (18), № 3. С. 343-349. [Glushkov A.N., Polenok E.G., Kostyanko M.V., Titov V.A., Vafin I.A., Ragozhina S.E. Mutual effects of antibodies to benzo[a]pyrene, estradiol and progesterone on the lung cancer risks. Rossiyskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2015, Vol. 9 (18), no. 3, pp. 343-349. (In Russ.)]][Глушков А.Н., Поленок Е.Г., Гордеева Л.А., Мун С.А., Костянко М.В., Антонов А.В., Титов В.А., Вержбицкая Н.Е., Вафин И.А. Иммунологический дисбаланс при раке молочной железы и раке легкого у женщин в постменопаузе // Медицинская иммунология, 2018. Т. 20, № 6. С. 927-934. [Glushkov A.N., Polenok E.G., Gordeeva L.A., Mun S.A., Kostyanko M.V., Antonov A.V., Titov V.A., Verzhbitskaya N.E., Vafin I.A. Immunological imbalance in breast cancer and lung cancer in postmenopausal women. Meditsinskaya immunologiya = Medical Immunology, (Russia), 2018, Vol. 20, no. 6, pp. 927-934. (In Russ.)] doi: 10.15789/1563-0625-2018-6-927-934.][Глушков А.Н., Поленок Е.Г., Мун С.А., Гордеева Л.А., Костянко М.В., Колпинский Г.И., Луценко В.А., Антонов А.В., Титов В.А., Вафин И.А. Антитела к химическим канцерогенам и половым стероидам и содержание эстрадиола и прогестерона в сыворотке крови женщин больных раком молочной железы и мужчин больных раком легкого // Российский иммунологический журнал, 2020. Т. 23, № 1. С. 69-78. [Glushkov A.N., Polenok E.G., Mun S.A., Gordeeva L.A., Kostyanko M.V., Kolpinsky G.I., Lutsenko V.A., Antonov A.V., Titov V.A., Vafin I.A. Antibodies to the chemical carcinogens and sex steroids of estradiol and progesterone the serum levels of features in women and men with breast and lung cancer. Rossiyskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2020, Vol. 23, no. 1, pp. 69-78. (In Russ.)]][Глушков А.Н., Поленок Е.Г., Мун С.А., Гордеева Л.А., Костянко М.В., Луценко В.А., Колпинский Г.И., Брежнева Е.В., Вафин И.А. Индивидуальный иммунологический фенотип и гормональный баланс у женщин в постменопаузе // Российский иммунологический журнал, 2020. Т. 23, № 1. С. 61-68. [Glushkov A.N., Polenok E.G., Mun S.A., Gordeeva L.A., Kostyanko M.V., Lutsenko V.A., Kolpinskiy G.I., Brezhneva E.V., Vafin I.A. Immunological phenotype and hormonal balance in postmenopausal women. Rossiyskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2020, Vol. 23, no. 1, pp. 61-68. (In Russ.)]][Глушков А.Н., Поленок Е.Г., Мун С.А., Магарилл Ю.А., Гордеева Л.А., Луценко В.А., Колпинский Г.И., Костянко М.В., Вафин И.А. Влияние анти-антител к эстрадиолу и прогестерону на содержание гормонов в сыворотке крови здоровых женщин и больных раком молочной железы // Сибирский онкологический журнал, 2020. Т. 19, № 2. С. 62-69. [Glushkov A.N., Polenok E.G., Mun S.A., Magarill Y.A., Gordeeva L.A., Lutsenko V.A., Kolpinskiy G.I., Kostyanko M.V., Vafin I.A. Effect of anti-antibodies to estradiol and progesterone on the concentration of hormones in the blood serum of healthy women and breast cancer patients. Sibirskiy onkologicheskiy zhurnal = Siberian Journal of Oncology, 2020, Vol. 19, no. 2, pp. 62-69. (In Russ.)]][Agudo A., Peluso M., Munnia A., Luján-Barroso L., Sánchez M.J., Molina-Montes E., Sánchez-Cantalejo E., Navarro C., Tormo M.J., Chirlaque M.D., Barricarte A., Ardanaz E., Amiano P., Dorronsoro M., Quirós J.R., Piro S., Bonet C., Sala N., González C.A. Aromatic DNA adducts and risk of gastrointestinal cancers: a case-cohort study within the EPIC-Spain. Cancer Epidemiol. Biomarkers Prev., 2012, Vol. 21, no. 4, pp. 685-692.][Albini A., Rosano C., Angelini G., Amaro A., Esposito A.J., Maramotti S., Noonan D.M., Pfeffer U. Exogenous hormonal regulation in breast cancer cell by phytoestrogens and endocrine disruptors. Curr. Med. Chem., 2014, Vol. 21, no. 9, pp. 1129-1145.][Al-Saleh I., Arif J., El-Doush I., Al-Sanea N., Jabbar A.A., Billedo G., Shinwari N., Mashhour A., Mohamed G. Carcinogen DNA adducts and the risk of colon cancer: case-control study. Biomarkers, 2008, Vol. 13, no. 2, pp. 201-216.][Ambrosone C.B., Abrams S.M., Gorlewska-Roberts K., Kadlubar F.F. Hair dye use, meat intake, and tobacco exposure and presence of carcinogen-DNA adducts in exfoliated breast ductal epithelial cells. Arch. Biochem. Biophys., 2007, Vol. 464, no. 2, pp. 169-175.][Bourtourault M., Shacoori V., Guerin J., Saiag B., Rault B. Effects of simultaneous active immunization against 17 beta-estradiol and testosterone on pituitary and ovarian activity in the rat. Res. Commun. Chem. Pathol. Pharmacol., 1991, Vol. 72, no. 3, pp. 273-284.][Caldwell B.V., Tillson S.A., Esber H., Thorneycroft I.H. Survival of tumors after immunization against oestrogens. Nature, 1971, Vol. 231, no. 5298, pp. 118-119.][Cavalieri E.L., Rogan E.G., Zahid M. Critical depurinating DNA adducts: Estrogen adducts in the etiology and prevention of cancer and dopamine adducts in the etiology and prevention of Parkinson’s disease. Int. J. Cancer., 2017, Vol. 141, no. 6, pp. 1078-1090.][Ceppi M., Munnia A., Cellai F., Bruzzone M., Peluso M.E.M. Linking the generation of DNA adducts to lung cancer. Toxicology, 2017, no. 390, pp. 160-166.][Černohorská H., Klimešová S., Lepša L., Jinoch P., Milcová A., Schmuczerová J., Topinka J., Lábaj J. Influence of immunization with non-genotoxic PAH-KLH conjugates on the resistance of organisms exposed to benzo[a]pyrene. Mut. Res., 2012, Vol. 742, no.1-2, pp. 2-10.][Charles G.D., Bartles M.J., Zacharewski T.R., Gollapudi B.B., Freshour N.L., Carney E.W. Activity of benzo[a]pyrene and its hydroxylated metabolites in an estrogen receptor-alpha reporter gene assay. Toxicol. Sci., 2000, Vol. 55, no. 2, pp. 320-326.][Chen Z., Zhang Y., Yang J., Jin M., Wang X.W., Shen Z.Q., Qiu Z., Zhao G., Wang J., Li J.W. Estrogen promotes benzo[a]pyrene-induced lung carcinogenesis through oxidative stress damage and cytochrome c-mediated caspase-3 activation pathway in female mice. Cancer. Lett., 2011, Vol. 308, no. 1, pp. 14-22.][Chlebowski R.T., Anderson G.L., Aragaki A.K., Manson J.E., Stefanick M.L., Pan K., Barrington W., Kuller L.H., Simon M.S., Lane D., Johnson K.C., Rohan T.E., Gass M.L.S., Cauley J.A., Paskett E.D., Sattari M., Prentice R.L. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women’s health initiative randomized clinical trials. JAMA, 2020, Vol. 324, no. 4, pp. 369-380.][Dimou N.L., Papadimitriou N., Gill D., Christakoudi S., Murphy N., Gunter M.J., Travis R.C., Key T.J., Fortner R.T., Haycock P.C., Lewis S.J., Muir K., Martin R.M., Tsilidis K.K. Sex hormone binding globulin and risk of breast cancer: a Mendelian randomization study. Int. J. Epidemiol., 2019, Vol. 48, no. 3, pp. 807-816.][Falk R.T., Manson J.E., Barnabei V.M., Anderson G.L., Brinton L.A., Rohan T.E., Cauley J.A., Chen C., Coburn S.B., Pfeiffer R.M., Reding K.W., Sarto G.E., Wentzensen N., Chlebowski R.T., Xu X., Trabert B. Estrogen metabolism in menopausal hormone users in the women’s health initiative observational study: Does it differ between estrogen plus progestin and estrogen alone? Int. J. Cancer, 2019, Vol. 144, no. 4, pp. 730-740.][Glushkov A.N., Polenok E.G., Mun S.A., Gordeeva L.A. Immunization against environmental chemical carcinogens: pro and contra. Med. Hypotheses, 2019, Vol. 131, 109303. doi: 10.1016/j.mehy.2019.109303.][Greiner M., Pfeiffer D., Smith R.D. Principles and practical application of the receiver operating characteristic analysis for diagnostic test. Prev. Vet. Med., 2000, Vol. 45, pp. 23-41.][Grigoryeva E.S., Kokova D.A., Gratchev A.N., Cherdyntsev E.S., Buldakov M.A., Kzhyshkowska J.G., Cherdyntseva N.V. Smoking-related DNA adducts as potential diagnostic markers of lung cancer: new perspectives. Exp. Oncol., 2015, Vol. 37, no. 1, pp. 5-12.][Grova N., Prodhomme E.J., Schellenberger M.T., Farinelle S., Muller C.P. Modulation of carcinogen bioavailability by immunisation with benzo[a]pyrene – conjugate vaccines. Vaccine, 2009, Vol. 27, no. 31, pp. 4142-4151.][Hirose T., Morito K., Kizu R., Toriba A., Hayakawa K., Ogawa S., Inoue S., Muramatsu M., Masamune Y. Estrogenic/antiestrogenic activities of benzo[a]pyrene monohydroxy derivatives. J. Health Sci., 2001, Vol. 47, no. 6, pp. 552-558.][Jonsson C., Stål P., Sjöqvist U., Akerlund J.E., Löfberg R., Möller L. DNA adducts in normal colonic mucosa from healthy controls and patients with colon polyps and colorectal carcinomas. Mutagenesis, 2010, Vol. 25, no. 5, pp. 499-504.][Kang S.C., Lee B.M. Effect of estrogen receptor (ER) on benzo[a]pyrene-DNA adduct formation in human breast cancer cells. J. Toxicol. Environ. Health A., 2005, Vol. 68, no. 21, pp. 1833-1840.][Lin S., Lin C.J., Hsieh D.P., Li L.A. ERα phenotype, estrogen level, and benzo[a]pyrene exposure modulate tumor growth and metabolism of lung adenocarcinoma cells. Lung Cancer, 2012, Vol. 75, no. 3, pp. 285-292.][Maselli A., Capoccia S., Pugliese P., Raggi C., Cirulli F., Fabi A., Malorni W., Pierdominici M., Ortona E. Autoantibodies specific to estrogen receptor alpha act as estrogen agonists and their level correlate with breast cancer cell proliferation. Oncoimmunology, 2016, Vol. 5, no. 2, e1074375. doi: 10.1080/2162402X.2015.1074375.][McCreery M.Q., Balmain A. Chemical carcinogenesis models of cancer: back to the future. Annu. Rev. Cancer Biol., 2017, Vol. 1, pp. 295-312.][Mohammed H., Russell I.A., Stark R., Rueda O.M., Hickey T.E., Tarulli G.A., Serandour A.A., Birrell S.N., Bruna A., Saadi A., Menon S., Hadfield J., Pugh M., Raj G.V., Brown G.D., D’Santos C., Robinson J.L., Silva G., Launchbury R., Perou C.M., Stingl J., Caldas C., Tilley W.D., Carroll J.S. Progesterone receptor modulates ERα action in breast cancer. Nature, 2015, Vol. 523, no. 7560, pp. 313-317.][Nelson H.D., Fu R., Zakher B., Pappas M., McDonagh M. Medication use for the risk reduction of primary breast cancer in women: updated evidence report and systematic review for the US preventive services task force. JAMA, 2019, Vol. 322, no. 9, pp. 868-886.][Patisaul H.B., Jefferson W. The pros and cons of phytoestrogens. Front. Neuroendocrinol., 2010, Vol. 31, no. 4, pp. 400-419.][Peluso M., Munnia A., Hoek G., Krzyzanowski M., Veglia F., Airoldi L., Autrup H., Dunning A., Garte S., Hainaut P., Malaveille C., Gormally E., Matullo G., Overvad K., Raaschou-Nielsen O., Clavel-Chapelon F., Linseisen J., Boeing H., Trichopoulou A., Trichopoulos D., Kaladidi A., Palli D., Krogh V., Tumino R., Panico S., Bueno-De-Mesquita H.B., Peeters P.H., Kumle M., Gonzalez C.A., Martinez C., Dorronsoro M., Barricarte A., Navarro C., Quiros J.R., Berglund G., Janzon L., Jarvholm B., Day N.E., Key T.J., Saracci R., Kaaks R., Riboli E., Vineis P. DNA adducts and lung cancer risk: a prospective study. Cancer Res., 2005, Vol. 65, no. 17, pp. 8042-8048.][Rawlings N.C., Kennedy S.W., Henricks D.M. The active immunization of the cyclic ewe against an estrone protein conjugate. Theriogenology, 1979, Vol. 12, no. 3, pp. 139-151.][Rosenberg M., Amir D., Folman Y. The effect of active immunization against progesterone on plasma concentrations of total and free progesterone, estradiol-17beta and LH in the cyclic ewe. Theriogenology, 1987, Vol. 28, no. 4, pp. 417-426.][Rundle A., Richards C., Neslund-Dudas C., Tang D., Rybicki B.A. Neighborhood socioeconomic status modifies the association between individual smoking status and PAH-DNA adduct levels in prostate tissue. Environ. Mol. Mutagen., 2012, Vol. 53, no. 5, pp. 384-391.][Rundle A., Tang D., Hibshoosh H., Estabrook A., Schnabel F., Cao W., Grumet S., Perera F.P. The relationship between genetic damage from polycyclic aromatic hydrocarbons in breast tissue and breast cancer. Carcinogenesis, 2000, Vol. 21, no. 7, pp. 1281-1289.][Rybicki B.A., Neslund-Dudas C., Bock C.H., Rundle A., Savera A.T., Yang J.J., Nock N.L., Tang D. Polycyclic aromatic hydrocarbon – DNA adducts in prostate and biochemical recurrence after prostatectomy. Clin. Cancer Res., 2008, Vol. 14, no. 3, pp. 750-757.][Sagiv S.K., Gaudet M.M., Eng S.M., Abrahamson P.E., Shantakumar S., Teitelbaum S.L., Bell P., Thomas J.A., Neugut A.I., Santella R.M., Gammon M.D. Polycyclic aromatic hydrocarbon-DNA adducts and survival among women with breast cancer. Environ. Res., 2009, Vol. 109, no. 3, pp. 287-291.][Schellenberger M.T., Farinelle S., Willième S., Muller C.P. Evaluation of adjuvants for a candidate conjugate vaccine against benzo[a]pyrene. Hum. Vaccin., 2011, Vol. 7, no. 1, pp. 166-173.][Sestak I. Preventative therapies for healthy women at high risk of breast cancer. Cancer Manag. Res., 2014, Vol. 6, pp. 423-430.][Sömjen D., Kohen F., Lieberherr M. Nongenomic effects of an anti-idiotypic antibody as an estrogen mimetic in female human and rat osteoblasts. J. Cell. Biochem., 1997, Vol. 65, no. 1, pp. 53-66.][Tang D., Kryvenko O.N., Wang Y., Jankowski M., Trudeau S., Rundle A., Rybicki B.A. Elevated polycyclic aromatic hydrocarbon-DNA adducts in benign prostate and risk of prostate cancer in African Americans. Carcinogenesis, 2013, Vol. 34, no. 1, pp. 113-120.][Tassignon J., Haeseleer F., Borkowski A. Natural antiestrogen receptor autoantibodies in man with estrogenic activity in mammary carcinoma cell culture: study of their mechanism of action; evidence for involvement of estrogen-like epitopes. J. Clin. Endocrinol. Metab., 1997, Vol. 82, no. 10, pp. 3464-3470.][Yager J.D. Mechanisms of estrogen carcinogenesis: The role of E2/E1 – quinone metabolites suggests new approaches to preventive intervention – A review. Steroids, 2015, Vol. 99, Pt A, pp. 56-60.][Yang L., Zahid M., Liao Y., Rogan E.G., Cavalieri E.L., Davidson N.E., Yager J.D., Visvanathan K., Groopman J.D., Kensler T.W. Reduced formation of depurinating estrogen-DNA adducts by sulforaphane or KEAP1 disruption in human mammary epithelial MCF-10A cells. Carcinogenesis, 2013, Vol. 34, no. 11, pp. 2587-2592.][Zeng Z., Jiang X., Li X., Wells A., Luo Y., Neapolitan R. Conjugated equine estrogen and medroxyprogesterone acetate are associated with decreased risk of breast cancer relative to bioidentical hormone therapy and controls. PLoS ONE, 2018, Vol. 13, no. 5, e0197064. doi: 10.1371/journal.pone.0197064.]